NCT00891813View on ClinicalTrials.gov

Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose

PHASE4CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions
Secondary HyperparathyroidismRenal Insufficiency, ChronicParathyroid HormoneHemodialysisHypercalcemia
Interventions
DRUG

Zemplar (paricalcitol)

Zemplar (paricalcitol) dose will be calculated mcg=PARATHYROID HORMONE level/100; this will be provided 3 times per week. Dose will be adjusted by 2-4 mcg every 4 weeks according to the parathyroid hormone level.

Trial Locations (3)

CALLAO 2

Site Reference ID/Investigator# 21401, Callao

Lima-11

Site Reference ID/Investigator# 23857, Lima

Unknown

Site Reference ID/Investigator# 10941, Lima

Sponsors

Lead Sponsor

Abbott
All Listed Sponsors
lead

Abbott

INDUSTRY

NCT00891813 - Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose | Biotech Hunter | Biotech Hunter